$Monopar Therapeutics (MNPR.US)$2024年9月30日结束的第三季度结果与2023年9月30日结束的第三季度结果进行比较 现金及净损失 Cash and cash equivalents as of September 30, 2024, were $600万. As noted above, the Company completed a registered public offering on October 30, 2024 that yielded net proceeds to the Company of approximately $1770万, after deducting placement agent fees and other estimated offering expenses. Monopar project...
Daily Investors : 这条发帖,我发誓将会成为那些没有抓住机会的人们的灵感。耐心。
https://snsim.moomoo.com/share/server/Apx2B?lang=en-us
Kevin Matte : 不是你的问题!